LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Lineage Cell Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$0.95−0.03 (-2.61%)

Close on Oct 19, 2026

Market cap: $249.13M
P/E (TTM): –
Dividend yield: –

Lineage Cell Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	15	9.50	8.95	15	4.34	1.83	3.52	4.99	3.46	5.92	7.04	5.24	4.43	3.92	4.43	3.71	1.93
Cost of Revenue	–	0.33	0.67	0.73	1.43	0.39	0.41	0.30	0.17	0.36	1.11	0.84	0.79	0.43	0.08	0.03	–
Gross Profit	–	9.17	8.27	14	2.92	1.44	3.10	4.69	3.29	5.57	5.93	4.41	3.64	3.48	4.35	3.68	–
Research & Development	18	12	16	14	34	12	18	21	24	36	43	38	27	18	14	8.19	-3.18
General & Administrative	18	18	17	23	18	16	24	25	20	28	29	18	16	10	9.34	5.34	-2.26
Operating Expenses	–	–	33	36	52	28	42	46	44	65	72	55	60	28	23	14	5.45
Total Costs & Expenses	51	31	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-37	-21	-25	-23	-49	-26	-39	-42	-39	-59	-66	-51	-56	-25	-19	-9.85	-3.52
Interest & Investment Income	–	–	–	–	–	1.04	1.69	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	–	–	–	–	–	–	–	-4.67	-0.04	0	0	–	–	–	–
Other Non-Operating Income	-32	2.90	1.45	-3.29	5.94	4.52	20	-5.34	16	78	3.16	-0.47	-0.20	-0.31	0.24	-2.34	-1.62
Asset Impairment Charges	–	0	0	0	–	–	–	–	–	–	0.00	0.01	-0.01	0.02	0.01	0.00	0.00
Gain (Loss) on Investments	-0.01	-0.01	-0.18	-2.19	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	0.01	0.01	0.11	–	–	0	3.69	0	0	-0.01	-0.01	0	0
Legal Settlements	–	–	–	-3.50	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-69	-19	-23	-26	-43	-22	-19	-47	-23	19	-63	-51	-56	-25	-18	–	–
Income Tax Expense	-5.28	0	-1.80	0.54	–	-1.24	-7.41	0.35	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-63	-19	-21	-26	-43	-21	-12	-47	-23	19	-58	-44	-53	-25	-18	-12	-5.14
Minority Interest in Earnings	0.17	0.03	0.01	-0.08	-0.25	-0.04	-0.12	-0.79	-3.31	-15	-11	-7.37	-9.03	-3.88	-1.93	-1.00	0.00
Net Income	-64	-19	-21	-26	-43	-21	-12	-46	-20	34	-47	-36	-44	-21	-17	-11	-5.14
Preferred Dividends	–	–	–	–	–	–	–	–	–	0	-0.42	0.09	0	0	–	–	–
Net Income to Common	–	–	–	–	–	–	–	–	-20	34	-47	-36	-44	-21	–	–	–
EPS (Basic)(per share)	-0.28	-0.09	-0.12	-0.15	-0.26	-0.14	-0.08	-0.36	-0.17	0.35	-0.59	-0.55	-0.81	-0.44	-0.35	-0.28	-0.18
EPS (Diluted)(per share)	-0.28	-0.09	-0.12	-0.15	-0.26	-0.14	-0.08	-0.36	-0.17	0.34	-0.59	-0.55	-0.81	-0.44	-0.35	-0.28	-0.18
Shares Outstanding (Basic, Weighted)(shares)	230	200	173	170	165	0.15	0.15	0.13	114	97	80	66	54	49	47	40	–
Shares Outstanding (Diluted, Weighted)(shares)	230	200	173	170	0.16	0.15	0.15	0.13	114	100	80	66	54	49	47	40	–
EBITDA	-36	-21	-24	-22	-49	-26	-38	-41	-38	-58	-65	-50	–	–	–	–	–
Net Interest Income	–	–	–	0.83	0.00	1.04	–	–	–	–	-0.64	-0.09	0	0.02	0.03	-0.12	-1.65

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -205.2%
Net margin: -246.6%
Return on equity, FY2025: -103.4%

Financial strength

Current ratio: 6.61
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 466.0%

Valuation

P/E ratio: –
Price to sales: 19.04
Price to book: 4.09
Dividend yield: –